Suppr超能文献

挽救性经腹会阴联合切除术治疗肛门鳞癌:30 年单中心经验。

Salvage Abdominoperineal Resection for Squamous Cell Anal Cancer: A 30-Year Single-Institution Experience.

机构信息

Department of Surgical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Department of Radiation Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

出版信息

Ann Surg Oncol. 2018 Jul;25(7):1970-1979. doi: 10.1245/s10434-018-6483-9. Epub 2018 Apr 24.

Abstract

BACKGROUND

Failure of chemoradiotherapy (CRT) for anal squamous cell carcinoma (SCC) results in persistent or recurrent anal SCC. Treatment with salvage abdominoperineal resection (APR) can potentially achieve cure. The aims of this study are to analyze oncological and surgical outcomes of our 30-year experience with salvage APR for anal SCC after failed CRT and identify prognostic factors for overall survival (OS).

METHODS

All consecutive patients who underwent salvage APR between 1990 and 2016 for histologically confirmed persistent or recurrent anal SCC after failed CRT were retrospectively analyzed.

RESULTS

Forty-seven patients underwent salvage APR for either persistent (n = 24) or recurrent SCC (n = 23). Median OS was 47 months [95% confidence interval (CI) 10.0-84.0 months] and 5-year survival was 41.6%, which did not differ significantly between persistent or recurrent disease (p = 0.551). Increased pathological tumor size (p < 0.001) and lymph node involvement (p = 0.014) were associated with impaired hazard for OS on multivariable analysis, and irradical resection only (p = 0.001) on univariable analysis. Twenty-one patients developed local recurrence after salvage APR, of whom 8 underwent repeat salvage surgery and 13 received palliative treatment. Median OS was 9 months (95% CI 7.2-10.8 months) after repeat salvage surgery and 4 months (95% CI 2.8-5.1 months) following palliative treatment (p = 0.055).

CONCLUSIONS

Salvage APR for anal SCC after failed CRT resulted in adequate survival, with 5-year survival of 41.6%. Negative prognostic factors for survival were increased tumor size, lymph node involvement, and irradical resection. Patients with recurrent anal SCC after salvage APR had poor prognosis, irrespective of performance of repeat salvage surgery, which never resulted in cure.

摘要

背景

经放化疗(CRT)治疗后,肛门鳞状细胞癌(SCC)仍出现局部进展或复发,需要行挽救性腹会阴联合切除术(APR)治疗,以争取治愈。本研究旨在分析我们 30 年来 CRT 失败后行挽救性 APR 治疗肛门 SCC 的肿瘤学和手术结果,并确定总生存(OS)的预后因素。

方法

回顾性分析了 1990 年至 2016 年间因 CRT 失败后经组织学证实为持续性或复发性肛门 SCC 而行挽救性 APR 的所有连续患者。

结果

47 例患者因持续性(n = 24)或复发性 SCC(n = 23)而行挽救性 APR。中位 OS 为 47 个月(95%CI:10.0-84.0 个月),5 年生存率为 41.6%,持续性和复发性疾病之间的 5 年生存率无显著差异(p = 0.551)。多变量分析显示,肿瘤病理大小增加(p < 0.001)和淋巴结受累(p = 0.014)与 OS 风险降低相关,单变量分析显示,非根治性切除(p = 0.001)也是影响 OS 的一个因素。21 例患者在挽救性 APR 后出现局部复发,其中 8 例再次接受挽救性手术,13 例接受姑息治疗。再次挽救性手术后的中位 OS 为 9 个月(95%CI:7.2-10.8 个月),姑息治疗后的中位 OS 为 4 个月(95%CI:2.8-5.1 个月)(p = 0.055)。

结论

经 CRT 治疗失败后行挽救性 APR 治疗肛门 SCC 可获得较好的生存,5 年生存率为 41.6%。生存的负性预后因素为肿瘤大小增加、淋巴结受累和非根治性切除。挽救性 APR 后复发的肛门 SCC 患者预后较差,无论是否行再次挽救性手术,均无法治愈。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50c6/5976705/f41a3e934659/10434_2018_6483_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验